Indonesia's Agency for Food and Drug Control (BPOM) Holds Workshop on Vaccine Quality Management

Jun 16, 2013 19:00 JST

Source: PT Bio Farma (Persero)

Bandung, W Java, Indonesia, Jun 16, 2013 - (ACN Newswire) - Indonesia's Agency for Food and Drug Control (BPOM) is to hold a workshop on the quality management for vaccine making of which it has good experience to share with member states of the Organization of Islamic Conference (OIC).

The workshop is to be held on 17 June 2013 alongside the on-going 2nd meeting of vaccine- and medicine-manufacturers of OIC member states in the city of Bandung, West Java province. Delegates and experts from nine countries that already have their vaccine making facilities out of the total 57 OIC member countries are attending the meeting which runs from 16 to 19 June, 2013.

The BPOM workshop is aimed sharing Indonesian experience with other OIC member states on strengthening National Regulation Authority (NRA)'s function in vaccine manufacturing for global markets. NRAs are national regulatory agencies responsible for ensuring that products released for public distribution (normally pharmaceuticals and biological products, such as vaccines) are evaluated properly and meet international standards of quality and safety.

Countries producing vaccines need to exercise six critical control functions, and exercise them in a competent and independent manner, backed up with enforcement power. The six functions are a published set of requirements for licensing, surveillance of vaccine field performance, system of lot release, use of laboratory when needed, regular inspections for good manufacturing practices (GMP) and clinical performance evaluation.

The workshop will start with keynote remarks by BPOM head Lucky S. Slamet, said workshop organizers. Bio Farma will take part in the workshop and share the experiences that the 123-year old vaccine making company has, organizers said.

Bio Farma Sales & Marketing Director Dr. Mahendra Suhardono is scheduled to speak on quality management system (Manufacture, Pre Qualification of Vaccine) in a way to meeting the GMP as set out by the WHO for its prequalification so that the vaccine products are exportable.

Dr. Suhardono is expected to speak about how Bio Farma has been able to maintain an integrated system of quality control management and efforts on keeping it update with latest GMP requirements. Bio Farma is Indonesia's only vaccine manufacturer whose products have been recognized by WHO since 1997, so that the company can supply its products to over 120 countries worldwide.

Currently the needs for Expanded Program on Immunization (EPI) vaccines in Indonesia have been supplied solely by Bio Farma by producing and distributing over 1.7 billion doses of vaccine per year to meet the needs of EPI vaccine for national immunization program.

Bio Farma has an outstanding international reputation based on the WHO prequalification for all of its EPI vaccine products, and has also implemented green industry and is environmently friendly. WHO acknowledges that Bio Farma vaccine products are of high quality, efficacious, and affordable.

Bio Farma products are through the direct distribution or through various agencies such as UNICEF and PAHO. The company has obtained the Best Export Performance from the Indonesian Trade Ministry consecutively in 2010,2011, 2012 as evidence of its consistent exceptional performance.

Contact:

M. Rahman Rustan  
Corporate Secretary 
Bio Farma 
+62 22 2033755
+62 22 2041306
pr@biofarma.co.id

Source: PT Bio Farma (Persero)
Sectors: BioTech

Latest Release

Hitachi delivers a turnkey rail solution for Ho Chi Minh City's first urban railway Line 1 in Vietnam
Dec 24, 2024 13:19 JST

Nissan and Honda sign MOU to consider business integration
Dec 24, 2024 11:18 JST

Olympus Named to Dow Jones Sustainability World Index for the Fourth Consecutive Year
Dec 24, 2024 11:00 JST

Nissan, Honda, and Mitsubishi Motors sign MOU on collaborative considerations
Dec 24, 2024 10:54 JST

GAC Honda Begins Operation of New Energy Vehicle (NEV) Production Factory in Guangzhou, China
Dec 24, 2024 10:23 JST

Sarawak Premier Makes Inaugural Visit to Mitsubishi Power's Takasago Hydrogen Park
Dec 24, 2024 10:10 JST

Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
Dec 23, 2024 17:22 JST

Fujitsu drives chemical industry logistics DX with participation in joint logistics demonstration
Dec 23, 2024 13:30 JST

Mitsubishi Motors Cumulative Production Reaches One Million Units in Indonesia
Dec 20, 2024 17:35 JST

Contract Renewed on Operation and Maintenance (O&M) Services for APM System at Washington Dulles International Airport
Dec 20, 2024 17:24 JST

Toyota Launches Alphard and Vellfire PHEV Models in Japan
Dec 20, 2024 15:38 JST

6G Begins! Embarking on a New Journey of Global Interoperable Standards
Dec 19, 2024 16:50 JST

MI LNG Company to Change Corporate Name to MILES
Dec 19, 2024 13:49 JST

Two Honda 0 Series Prototype Models to Premiere at CES 2025
Dec 19, 2024 12:30 JST

Honda Presents World Premiere of Honda S+ Shift, Next-generation e:HEV Technology
Dec 19, 2024 12:13 JST

NEC Completes new Asia Pacific submarine cable
Dec 19, 2024 12:02 JST

Enablement of JCB Contactless Payment at All NJ TRANSIT Contactless Bus and Light Rail Validators in New Jersey, New York, and Pennsylvania
Dec 19, 2024 12:00 JST

Honda Presents Next-generation e:HEV Technologies at Press Briefing on Honda e:HEV Business and Technology
Dec 18, 2024 17:50 JST

MHI Appoints CTO Eisaku Ito as Next President & CEO, Announces Changes in Board and Executive-level Personnel
Dec 18, 2024 17:38 JST

Honda to Utilize Existing Powertrain Unit Factory to Establish New Production Plant for Next-generation Fuel Cell System in Japan
Dec 18, 2024 17:22 JST

More Latest Release >>

Latest Release

Related Release